News Release

April 18, 2025

Perseus Proteomics, Inc.
President & CEO: Takuya Yokokawa
e-mail: ir@ppmx.com

Announcement of Launch of Joint Research on Antibody Drug Discovery through Machine Learning with Institute of Science Tokyo

Perseus Proteomics Inc. (“the Company”) is pleased to announce that it has launched joint research on antibody drug discovery through machine learning with Institute of Science Tokyo.

The Company has been combining phage display technology with AI to enhance the efficiency and throughput of antibody selection from its antibody library. This joint research aims to quickly identify target antibodies by integrating the unique antibody library of the Company with the computational analysis techniques of Associate Professor Masahito Ohue from the School of Computing at Institute of Science Tokyo. Prof. Ohue's research group will be responsible for the analysis and selection of antibody sequences using computational chemistry and machine learning, while the Company will conduct experiments to evaluate the affinity, stability, and producibility of the predicted antibodies, providing the necessary data.

By synergizing the strengths in biological experiments (Wet) with computational analysis (Dry), the Company anticipates improvements in machine learning accuracy and increased efficiency in the antibody selection process.

This joint research will further advance the development of antibody drugs against challenging antigens. There is no impact on the business results of the fiscal year ending March 31, 2026.

END